Amgen Inc. (NASDAQ:AMGN) has seen considerable market activity in recent times. It seems investors are repositioning their stakes in the biotech powerhouse, with numerous firms such as Brown Advisory Inc decreases positions. Yet, a significant number of firms, like Ferguson Wellman Capital, insist making large additions to their existing holdings.
Code Waechter LLC and
Cerity Partners LLC also made new investments. The stock's oscillating performance is noteworthy as it has outperformed the broader market in some instances, and in other instances it underperformed.
Bemarituzumab's Phase 3 study announcement and full results from MariTide's Phase 2 study reflect Amgen’s credible efforts in drug development. Notably, certain setbacks like the fall after Novo Nordisk released its weight loss drug trial data has attracted attention too, highlighting the intense competition in this sector. Through it all, investors remain engaged, indicated by a vast institutional ownership of 82%, portraying a robust belief in Amgen's long-term value and growth potential. All considered, the biotech's ability to draw investment during both upswings and downturns in the market underscores its overall resiliency.
Amgen AMGN News Analytics from Tue, 14 Jan 2025 08:00:00 GMT to Sat, 12 Jul 2025 23:01:06 GMT -
Rating 1
- Innovation 7
- Information 7
- Rumor -6
